JPMorgan analyst Cory Kasimov recommends using this morning’s pullback in shares of bluebird bio (BLUE) after the company announced an amendment to its CAR-T collaboration agreement with Celgene (CELG) as a buying opportunity. Kasimov says that while investors may view negatively the narrowing of the agreement to focus solely on targeting B-cell maturation antigen, bluebird now stands to more fully benefit if it works. He points out the agreement was always a high risk/high reward effort and not relevant to his thesis on shares over the intermediate term. Kasimov keeps an Overweight rating on bluebird with a $200 price target. The stock is down $6.77 to $178.00 in pre-market trading.